Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?
Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?
Evaluation of new anticancer therapies in randomized clinical trials (RCTs) is typically based on comparing a new treatment with a standard one, using a time-to-event end point such as overall survival or progression-free survival (PFS). Although the statistical framework underlying the design of these RCTs is centered on formal testing …